Salt Lake Tribune · Dec 5, 2019
Experts split sharply over experimental Alzheimer’s drug
(Charles Krupa | AP) Charles Flagg, who is stricken with Alzheimer's disease, sits for an infusion while participating in a study on the drug Aducanumab at Butler Hospital in Providence, R.I. New results were released on the experimental medicine whose maker claims it can slow the decline of Alzheimer's disease, the most common form of dementia. SAN DIEGO • A company that claims to have the first drug to slow mental decline from Alzheimer’s disease made its case to scientists Thursday but left them sharply divided over whether there’s enough evidence of effectiveness for the medicine to warrant federal approval.